« Previous
Next »
Schizophrenia Research
Volume 71, Issue 1
, Pages 155-165
, 1 November 2004
Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores
References
- . The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 2002;21(2):271–292
- . Logical inconsistencies in survey respondents' health state valuations—a methodological challenge for estimating social tariffs. Health Econ. 2003;12(7):529–544
-
.
Cost-effectiveness in Health and Medicine.
New York: Oxford Univ. Press; 1996;
- . Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. J. Psychiatr. Res. 2000;34(3):201–210
-
.
Validity and interpretation of preference-based measures of health-related quality of life [see comments].
Med. Care. 2000;38(9 Suppl.):II138, II150
-
.
Use of the internet to study the utility values of the public.
Proc.-AMIA Symp. 2002;440–444
-
.
Effects on preferences of violations of procedural invariance [in process citation].
Med. Decis. Mak. 1999;19(4):473–481
- . Measurement of the validity of utility elicitations performed by computerized interview. Med. Care. 1997;35(9):915–920
-
.
The effect of search procedures on utility elicitations.
Med. Decis. Mak. 1998;18(1):76–83
- . Estimation of utilities for the effects of depression from the SF-12. Med. Care. 2000;38(7):763–770
- . Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med. Care. 2000;38(10):1011–1021
-
.
Toward improved methods for measurement of utility: automated repair of errors in utility elicitations.
Med. Decis. Mak. 2003;23(1):1–9
- . Clustering and the design of preference—assessment surveys in healthcare [in process citation]. Health Serv. Res. 1999;34(5 Pt. 1):1033–1045
-
.
The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice.
J. Clin. Psychiatry. 1999;60(Suppl. 3):42–47
(discussion 48)
- . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials [published erratum appears in J. Clin. Psychiatry 1998 Apr;59(4):200]. J. Clin. Psychiatry. 1997;58(12):538–546
- . Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch. Gen. Psychiatry. 2003;60(1):82–91
-
.
Capturing the Heterogeneity of Schizophrenia Disease States.
Schizophrenia Research. 2003;
-
.
Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36.
Med. Decis. Mak. 2001;21(2):105–112
- . Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med. Care. 2003;41(2):208–217
- . Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int. Clin. Psychopharmacol. 1996;11(2):101–108
-
.
Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.
Med. Decis. Mak. 1998;18(2 Suppl.):S68–S80
- . Empirically defined health states for depression from the SF-12. Health Serv. Res. 1998;33(4 Pt. 1):911–928
- . One thousand health-related quality-of-life estimates. Med. Care. 2000;38(6):583–637
-
.
Falling Through the Net [IV]: Toward Digital Inclusion.
Washington, DC: U.S. Dept. of Commerce National Telecommunications and Information Administration; 2000;
- . Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS study group. Psychopathology. 1997;30(5):263–274
PII: S0920-9964(03)00348-7
doi: 10.1016/j.schres.2003.10.010
© 2004 Elsevier B.V. All rights reserved.
« Previous
Next »
Schizophrenia Research
Volume 71, Issue 1
, Pages 155-165
, 1 November 2004
